John Aunins Net Worth & Insider Trades

John Aunins - Chief Technology Officer & EVP, Seres Therapeutics, Inc

As of December 19, 2018

What is John Aunins's Net Worth?

The current estimated net worth of Seres Therapeutics, Inc's Chief Technology Officer & EVP, John Aunins, is estimated to be about $3.81M . John Aunins owns about 85,250 units of Seres Therapeutics, Inc common stock. In the last 3 years at Seres Therapeutics, Inc, John Aunins has sold an estimated value of $3.25M worth.

What is John Aunins's Past Insider Trading?

John Aunins's largest purchase order was 187,500 units , worth over $90K on July 26, 2016. John Aunins's largest sale order was 18,640 units , worth over $595.36K on April 27, 2016. In total, John Aunins has made about 22 transactions over 3 years of their time at Seres Therapeutics, Inc. John Aunins usually trades in June, with the busiest year in 2018 and 2016. The most recent transaction was a sale order of 14,282 units , worth over $91.31K on December 19, 2018.

John G Aunins

Date Range: All Time
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What is John Aunins's' Mailing Address?

  • Mailing address is C/o Seres Health, Inc. 161 First Street Cambridge MA 02472 MA

Seres Therapeutics, Inc Executive Compensation

Name
Year
Salary
Bonus
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Eric D. Shaff 2020 $590,000 - $2,050,600 $486,750 $8,550 $3,135,900
Eric D. Shaff 2019 $540,000 - $1,231,148 $253,000 $8,400 $2,032,548
Thomas J. DesRosier 2020 $450,000 - $717,710 $261,000 $8,550 $1,437,260
Thomas J. DesRosier 2019 $428,300 - $379,641 $161,000 $8,400 $977,341
David S. Ege, Ph.D. 2020 $76,923 $65,000 $5,175,880 - $785 $5,318,587
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1609809/000119312521144988/d77986ddef14a.htm

What are Seres Therapeutics, Inc's Past Insider Trades?

Seres Therapeutics, Inc's most recent insider trade came on October 31, 2022 by David S Ege who sold 5,012 units worth $39.75K . In the last 6 years, insiders at Seres Therapeutics, Inc have sold an estimated value of $57.98M and bought an estimated value of $75.14M worth of shares. Insider trading is most common in June, with the busiest year in 2016. The most active traders at the company are Roger Pomerantz, Director,  John G Aunins, Chief Technology Officer & EVP,  and Eric D Shaff, CEO and President .

Seres Therapeutics, Inc. Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1